Equities researchers at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Free Report) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.
A number of other equities research analysts have also weighed in on the company. HC Wainwright cut their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Lake Street Capital cut their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th.
Check Out Our Latest Stock Report on Ekso Bionics
Ekso Bionics Price Performance
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The firm had revenue of $4.13 million for the quarter, compared to the consensus estimate of $6.00 million. During the same period last year, the company posted ($0.24) earnings per share. On average, equities research analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Recommended Stories
- Five stocks we like better than Ekso Bionics
- Comparing and Trading High PE Ratio Stocks
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- The Significance of Brokerage Rankings in Stock Selection
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What Is WallStreetBets and What Stocks Are They Targeting?
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.